Androgen Receptor Antagonists
-
Subject Areas on Research
- Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.
- Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.
- Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
- Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
- Beyond aggression: Androgen-receptor blockade modulates social interaction in wild meerkats.
- Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors.
- Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display.
- Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
- Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
- Enzalutamide in metastatic prostate cancer before chemotherapy.
- Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
- Increased survival with enzalutamide in prostate cancer after chemotherapy.
- Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
- Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
- Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells.
- Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
- Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
- Molecular determinants for enzalutamide-induced transcription in prostate cancer.
- New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.
- Novel therapies are changing treatment paradigms in metastatic prostate cancer.
- Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
- Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
- Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.
- Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
- Targeting the androgen receptor--theory and practice.
- The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
-
Keywords of People
- McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Pharmacology & Cancer Biology